CURRENT
ISSUE
1739

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has received accelerated approval from the FDA for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH; previously known as nonalcoholic steatohepatitis [NASH]) with moderate to advanced liver fibrosis in adults. It is the second drug and the first GLP-1 receptor agonist to be approved in the US for treatment of MASH; resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist, was granted accelerated approval for the same indication in 2024.1

 Continue reading

Coming Soon
Antiviral Drugs for Seasonal Influenza for 2025-2026
Deuruxolitinib (Leqselvi) for Severe Alopecia Areata
In Brief: Additional MRI Monitoring with Lecanemab (Leqembi)